Actym Therapeutics, Inc. is a cutting-edge biotechnology company based in Berkeley, CA. They specialize in engineering a new drug modality by utilizing a genetically modified bacterial vehicle to safely introduce therapeutic payloads and activate the immune response in the tumor microenvironment (TME). With their innovative approach, Actym aims to achieve targeted anti-tumor effects and deliver a new level of therapeutic impact for cancer patients across various tumor types.
By harnessing the power of their genetically modified bacterial vehicle, Actym is able to systemically administer cancer treatments that exploit TME-specific metabolites critical for bacterial enrichment. Their goal is to activate the immune response within the TME and achieve significant therapeutic outcomes. With a dynamic and innovative team, Actym Therapeutics is at the forefront of scientific innovation in the field of cancer research and treatment.
Generated from the website